Takeda’s experimental epilepsy drug soticlestat has failed not one but two phase 3 trials – in Dravet syndrome and Lennox-Gastaut syndrome – throwing the future of the programme in doubt.
In this instalment of our clinical trials round-ups, we look at life sciences research and development announced during the week of 3rd to 7th June, from early-stage onwards.
Takeda has made a strong play for a stake in the Alzheimer’s disease market, paying $100 million upfront for an option on AC Immune’s amyloid-targeting immunotherapy.
Takeda’s Iclusig has become the first targeted therapy approved by the FDA for use alongside chemotherapy as a first-line therapy for a rare form of acute lymphoblastic le
Ironwood Pharma has issued an upbeat assessment of phase 3 trial data with apraglutide for short bowel syndrome (SBS), but missed secondary outcome measures led to a sharp
The Life Sciences Generative AI Council aims to bring together the best minds in pharma, academia, and technology to advance the use of GenAI in life sciences R&D, seeking through pinpo